Pseudomonas
Aeruginosa Serotyping Kit
(FOR
RESEARCH)
Technology owned by University of Guelph.
Erfa Biotech operates under an agreement with Société en Commandite Biotech
CardioVision and Rougier Biotech Ltée.
Mouse monoclonal antibodies against serotype strains of Pseudomonas Aeruginosa
for serotyping and detection of Psedomonas Aeruginosa bacteremia
Erfa Biotech offers the most complete set of monoclonal antibodies against 17
standard (IATS) O serotype strains of Pseudomonas Aeruginosa. Antibodies
are very well characterized with respect to specificity, isotypes and strength.
These antibodies represent a bank of invaluable immunological reagents which
may have application in serotyping, epitope mapping, lipopolysaccharide structural
determination and studies of protection against Pseudomonas Aeruginosa.
One monoclonal antibody specific for each serogroup was chosen to form a kit
of antibodies. The format of the test is by the bacterial slide agglutination
test in which a small loopful of bacteria from an agar culture can be mixed
with a small drop (10 µl) of antibody solution on a microscope slide. Positive
agglutination can easily be seen within 10 second.
The advantage of such a test is that technologists from any research laboratory
will be able to perform the test, and no special training is required.
To kit has been tested in several clinical centers, which include: the British
Columbia's Children Hospital in Vancouver, the Cystic Fibrosis Centre of the
States Hospital of Denmark in Copenhagen, the Pediatric Group in the University
of Alberta Hospital in Edmonton, the University of Louisville, and the Montreal
General Hospital.
Thus far, we have tested the antibodies on more than 600 clinical isolates of
Pseudomonas Aeruginosa, and the results have shown good agreement on
all strains typable with the commercially available Difco Pseudomonas typing
sera. Additionally, the occurence of nontypable and polytypable strains was
drastically decreased when the monoclonal antibodies were used. Cross-reactions
that lead to polytypability and nontypability are common problems when the Difco
sera are used, and such cross-reactions are not observed with the use of our
monoclonal antibody kit. The antibodies were raised specifically against lipopolysaccharides
of Pseudomonas Aeruginosa, thus they can easily be mixed as a cocktail
of the 17 antibodies.
Pseudomonas Aeruginosa is a generally recognized bacterial pathogen of
nosocomial (hospital derived) infections, and it can also cause life threatening
diseases in patients with cancer, burn wounds, cystic fibrosis and in those
that have received immunosuppresive therapy.
Currently, the most common method used in hospitals is serotyping with a set
of typing antisera (polyclonal antibodies from rabbits). The set of antibodies
we have produced does not seem to have the usual batch to batch variability
and the cross-reaction problems mentioned previously.
| Assays | SKU # | Format |
| 100 | 76619 | kit |
| 50 | 76719 | kit |